📰 Authorization Application News
Page 3 - Authorization Application News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Authorization Application. Real-time updates on events, politics, business and more.
October 14, 2022
EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European
October 14, 2022
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the...
July 28, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
June 4, 2022
Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported StudiesCompletion of All Pre-Approval Inspections Required to Support EU Marketing Authorization Application; Anticipated European Commission Approval On-Track for Q4 2022SOUTH SAN...
February 23, 2022
Vifor Pharma reports sustained growth in 2021 Ad hoc announcement pursuant to Art. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment Iron franchise – Ferinject® / Injectafer® sales up...
February 8, 2022
Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025
February 8, 2022
08.02.2022 - Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 8, 2022 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2021. Business highlights QUVIVIQ (daridorexant) 25 mg and 50 mg approved by the US Food and ...
December 12, 2021
Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with... | December 12, 2021
December 9, 2021
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH New York, -- Intercept Pharmaceuticals,... | December 9, 2021
October 21, 2021
/PRNewswire/ -- Hansa on track to achieve key 2021 objectives: Agreements on funding obtained in three countries; HTA submissions in ten countries; and...